Asset Details
Do you wish to reserve the book?
Adoptive cell therapy using T cell receptors equipped with ICOS yields durable anti-tumor response
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Adoptive cell therapy using T cell receptors equipped with ICOS yields durable anti-tumor response
Do you wish to request the book?
Adoptive cell therapy using T cell receptors equipped with ICOS yields durable anti-tumor response
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Paper
Adoptive cell therapy using T cell receptors equipped with ICOS yields durable anti-tumor response
2025
Overview
Treatment with adoptively transferred T cells is challenged by limited longevity of therapeutic cells within tumors. To enhance the durability of anti-tumor T cell products, we have created T cell receptors (TCRs) with built-in co-stimulatory molecules. We observed that TCRs coupled to ICOS mediated exceptionally long-term responses including delay of tumor recurrence and cures in a mouse tumor model. TCR:ICOS T cells showed enhanced and antigen-specific production of inflammatory cytokines and resistance to exhaustion. Genetic ablation of ICOS-mediated activation of the PI3K-NFκB pathway neutralized the long-term anti-tumor effects. To translate TCR:ICOS to human T cells, we identified a single amino acid change in the cytosolic tail which was necessary for functional surface expression. Notably, the optimized receptor sustained performance of human T cells upon repeated stimulation across multiple antigen specificities. Collectively, we present a novel and uniformly applicable TCR:ICOS format that supports fitter T cell products for adoptive cell therapy.
Newly designed co-stimulatory TCR, with extracellular TCR-V and C domains coupled to CD28 transmembrane domain, and ICOS and CD3ε intracellular domains (in short TCR:ICOS) provides:
➢durable anti-tumor response and T cell persistence in mouse model➢inflammatory T cell phenotype and resistance to T cell exhaustion➢effects via PI3K and NFκB activation➢translation to human T cells upon single amino acid mutation in TCR:ICOS tail➢extension to multiple clinically relevant TCRs while preserving prolonged T cell fitness
durable anti-tumor response and T cell persistence in mouse model
inflammatory T cell phenotype and resistance to T cell exhaustion
effects via PI3K and NFκB activation
translation to human T cells upon single amino acid mutation in TCR:ICOS tail
extension to multiple clinically relevant TCRs while preserving prolonged T cell fitness
Publisher
Cold Spring Harbor Laboratory
Subject
